Ways to overcome the problem of obesity in a patient with reproductive system pathology

Abstract

The aim of the study is to substantiate the effectiveness of therapy in a patient with obesity and pathology of the reproductive system by using orlistat in combination with auxiliary substances. The subject of our study is a patient, H., 22 years old, the patient was diagnosed with ovarian dysfunction. E28.2. Glandular hyperplasia of the endometrium. N85. Grade 1 obesity (BMI 32.74). E 66. Glaucoma. H 40. The patient was prescribed didrogesterone from the 14th to the 25th day of the cycle, 100 mg 2 times a day, lifestyle modification, eating behavior, a reduction diet, a drug containing orlistat at a dosage of 120 mg in combination with excipients: acacia gum - 210 mg, lauryl sulfate -12 mg, mannitol 580 mg, crospovidone - 50 mg and magnesium stearate - 8 mg 3 times a day with meals.taking the ADEK vitamin complex 600 mg 1 capsule 1 time a day with meals. After 3 months, the weight decreased by 11 kg and amounted to 87 kg (BMI 29.07, which corresponds to overweight) after 6 months, by another 13 kg to 74 (BMI 24.73, which corresponds to normal body weight). The waist circumference has decreased from 82 cm to 71 cm. The progesterone level was 46.3 nmol/L, which corresponds to the average reference values. Ultrasound of the pelvic organs revealed no pathology, and the patient did not complain. There were no side effects. Thus, a significant decrease in the patient’s body weight against the background of the proposed method of therapy can be explained by the good tolerability of the treatment. The proposed treatment option for an obese patient made it possible to correct disorders of the reproductive system and, thus, prevent the occurrence of endometrial hyperplastic processes, dysmetabolic disorders and, subsequently, reduce the risk of reproductive losses during pregnancy planning.